Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial

INTRODUCTION: The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin. METHODS: This multicenter, open-label, 26-week phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Maniatis, Aristides K., Nadgir, Ulhas, Saenger, Paul, Reifschneider, Kent L., Abuzzahab, Jennifer, Deeb, Larry, Fox, Larry A., Woods, Katie A., Song, Wenjie, Mao, Meng, Chessler, Steven D., Komirenko, Allison S., Shu, Aimee D., Casella, Samuel J., Thornton, Paul S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501775/
https://www.ncbi.nlm.nih.gov/pubmed/35263755
http://dx.doi.org/10.1159/000524003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501775/
https://www.ncbi.nlm.nih.gov/pubmed/35263755
http://dx.doi.org/10.1159/000524003

Ejemplares similares